Last reviewed · How we verify
NCT07563088
SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
trial testing Postoperative Radiotherapy in Adenoid Cystic Carcinoma in 200 participants. Not yet recruiting.
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Status | Not yet recruiting |
| Enrollment | 200 |
| Start date | 1 May 2026 |
| Estimated completion | 1 May 2032 |
Drugs / interventions tested
- Postoperative Radiotherapy
- Observation
Conditions studied
- Adenoid Cystic Carcinoma — all drugs for Adenoid Cystic Carcinoma →
- Sinonasal Carcinoma — all drugs for Sinonasal Carcinoma →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Eligibility, any sex, with Adenoid Cystic Carcinoma or Sinonasal Carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07563088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Postoperative Radiotherapy
Trials testing the same drug.
- NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT05871307 — Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases · Phase 2 · recruiting
Other recruiting trials for Adenoid Cystic Carcinoma
Currently open trials in the same condition.
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT06805617 — A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers · Phase 2 · recruiting
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
- NCT06781567 — Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma · Phase 2 · recruiting
- NCT06118086 — Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma · Phase 1, PHASE2 · recruiting
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
- NCT07324317 — Validation of End-to-End Difficult Airway Pathway Planning Algorithm (EAP-LC) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07563088 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: recently
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07563088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing